The headline you have already read is that the weight-loss shot is becoming a pill. That part is true, and it is the least interesting thing about it. The scale readings from the oral candidates are, if anything, a small step down from injectable semaglutide. What changed this year is not how much weight the drugs take off. It is how they are made, and therefore who can plausibly get them.
What the pills actually did
Start with the numbers, because they are the reason people are excited and also the reason to slow down. Three oral GLP-1 drugs reported data in the first half of 2026. Aleniglipron, from Structure Therapeutics, took off 12.1 percent of body weight at its highest dose after 36 weeks in a phase 2 trial called ACCESS, 230 people, the middle of the drug's development, not the end. Lilly's orforglipron took off 11.2 percent at 72 weeks in ATTAIN-1, and that one is phase 3, more than 3,000 people, the trial that regulators actually judge. A third, CX11, claimed 11.5 percent, but only in a phase 2 press release with no published breakdown, so I would file it under "promising and unverified" and leave it there for now.
The difference is the factory
Stop there for a moment, because the excitement is pointed at the wrong number. The pill is not a better drug. It is a more shippable one. Orforglipron and aleniglipron are what chemists call small molecules. Semaglutide and tirzepatide, the drugs behind the familiar injectables, are peptides, short protein chains that have to be grown in engineered cells or stitched together on a solid support, then purified hard, then filled into sterile injectors, then kept cold from the factory to your refrigerator. A small molecule is made by ordinary chemical synthesis in an ordinary plant, pressed into a tablet, and left on a shelf at room temperature. That difference sounds like a footnote. It is the whole story.
Because a peptide injectable does not travel. The cold chain it needs, the unbroken run of refrigeration from plant to pharmacy, barely exists across much of the world. A shelf-stable tablet goes wherever aspirin goes. Lilly, which has staked the most on this, has said it expects to launch orforglipron worldwide without the supply crunch that has dogged the injectables, and analysts say an oral small molecule is far cheaper and simpler to make than a sterile peptide. That is an outside assessment, not a figure anyone has verified, but the direction is not in dispute. The pill is the version of this drug that a health system in a country without a cold chain could actually buy.
How the numbers line up
So how far below the injectables do the pills land, keeping in mind that no one has tested any of them against each other directly? Injectable semaglutide, sold as Wegovy, took off 14.9 percent over 68 weeks in its pivotal trial, STEP 1. Tirzepatide, sold as Zepbound, reached 20.9 percent over 72 weeks in SURMOUNT-1. The oral small molecules land below injectable semaglutide, and well below tirzepatide.
None of these were head-to-head trials; each drug was tested against its own placebo, in its own population, over its own number of weeks. Read the chart as a rough map, not a ranking, and note one asymmetry in it: the four phase 3 bars count everyone who started, while the aleniglipron bar is a phase 2 topline for the people who stayed on the drug, the more generous of the two bases, so if anything it flatters the pill against the shots beside it.
One clarification, because the word "pill" is doing too much work in the coverage. Novo Nordisk's oral Wegovy, the 25 milligram tablet the FDA approved in December 2025, is also a pill, and it took off 13.6 percent in its trial. But it is a peptide too, semaglutide wrapped in an absorption helper. It solves the needle. It does not solve the factory. When people say the oral GLP-1s will widen access, the drugs they should mean are the small molecules, not the peptide in tablet form.
Which brings us to the caveat that never makes the headline. These drugs are not gentle. In the orforglipron phase 3 trial, at the highest dose about one in three people had nausea and roughly one in four vomited, several times the rates on placebo. At that same dose, around one in ten stopped the drug entirely because of side effects, mostly stomach ones, against about one in forty who quit the placebo. Cheaper to ship does not mean easier to take. A pill you can get and then cannot tolerate is not access; it is a bottle in a drawer.
So here is where I would leave it. Only oral semaglutide is approved for weight loss as I write this; orforglipron, aleniglipron, and CX11 are still investigational, and every figure above is a trial average, not a forecast for any one person. The trials measured weight on a scale, over a fixed number of months, in people who were not you. What the small-molecule pill changes is not the size of the effect but the length of the road it can travel down. Whether that road actually reaches the people who have been priced and shipped out of these drugs is a question the chemistry cannot answer. That one is about who decides what a tablet costs, and the chemistry has never had a vote in that.
